Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Zaltoprofen (Soleton) is a Cox-1 and Cox-2 inhibitor, which is used for the treatment of arthritis.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | In stock | $ 35.00 | |
10 mg | In stock | $ 56.00 | |
25 mg | In stock | $ 89.00 | |
50 mg | In stock | $ 113.00 | |
100 mg | In stock | $ 153.00 | |
200 mg | In stock | $ 198.00 | |
500 mg | In stock | $ 329.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 62.00 |
Description | Zaltoprofen (Soleton) is a Cox-1 and Cox-2 inhibitor, which is used for the treatment of arthritis. |
Targets&IC50 | COX-2:0.34 μM (IC50), COX-1:1.3 μM (IC50) |
In vitro | Zaltoprofe is a non-steroidal anti-inflammatory drug (NSAID) that effectively inhibits cyclooxygenase-2 with minimal side effects on the gastrointestinal tract. Zaltoprofe binds to a specific site of the bradykinin B2 receptor protein, therefore, the effect of Zaltoprofen on the bradykinin-evoked response of adult DRG neurons can be investigated to investigate possible interaction sites. Zaltoprofen is the most effective inhibitor of bradykinin enhancing capsaicin-induced Ca2+ uptake into DRG neurons. Zaltoprofen also significantly inhibits bradykinin-induced 12-lipoxygenase (12-LOX) activity and slow bradykinin-induced release of the substance P from DRG neurons. Zaltoprofe showed a potent analgesic effect on BK (i.pl.)-induced hyperalgesia at 1 nmol, whereas loxoprofen or its active metabolite loxoprofen-SRS did not. Zaltoprofe also inhibits [Tyr8]-BK-induced nociception in that it is a type B2 receptor specific agonist; but does not affect the nociception induced by [lysine-DES-Arg9]-BK, which is type B1 BK receptor specific agonist. In primary sensory neurons, Zaltoprofe produces an analgesic effect of a bradykinin-induced nociceptive response by blocking the B(2) receptor-mediated pathway. Zaltoprofe completely inhibits Ca2+ increase induced by bradykinin, which is inhibited by the B(2) antagonist D-Arg-[Hyp(3), Thi(5,8), D-Phe(7)]-bradykinin, but not B(1) Antagonist. |
In vivo | After 8 hours of ConA treatment, mice were administrated of Zaltoprofen(10 mg/kg) resulting in inhibition of ConA-induced body weight loss. The combination of 10 mg/kg Zaltoprofen and ConA resulted in a 4-fold increase in food intake in mice compared to ConA only. Therefore, Zaltoprofen increased weight loss in ConA-treated mice. |
Synonyms | CN100, Soleton |
Molecular Weight | 298.36 |
Formula | C17H14O3S |
CAS No. | 74711-43-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: 29 mg/mL (97.2 mM)
DMSO: 56 mg/mL (187.7 mM)
H2O: < 1 mg/mL (insoluble or slightly soluble)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Zaltoprofen 74711-43-6 Immunology/Inflammation Neuroscience COX anti-inflammatory CN-100 COX-2 inhibit non-steroidal Inhibitor NSAID COX-1 CN100 Cyclooxygenase analgesic CN 100 Soleton inhibitor